foxo4-dri senolytic peptide human trials FOXO4-DRI: Trial Status, Cancer Research & Data Targeted Apoptosis of Senescent Cells
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging PMC The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect Buy FOXO4 DRI 10mg Peptide EU Tested Particle Peptides
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5



